ONWARD Medical (ONWD.BR)

Executive Summary

ONWARD Medical is a Netherlands-based medical device company pioneering non-invasive neurostimulation therapies for spinal cord injury (SCI). Its lead product, the ARC EX System, delivers transcutaneous spinal cord stimulation to improve upper limb function, addressing a significant unmet need in the SCI community. The company's ARC platform leverages decades of neuroscience research and has demonstrated promising clinical outcomes, positioning it as a potential game-changer in neurorehabilitation. With a strong intellectual property portfolio and a clear regulatory pathway, ONWARD is advancing toward commercialization in both the US and Europe. The company has completed several early-stage clinical trials showing meaningful improvements in hand and arm function, and is currently preparing for pivotal studies to support regulatory submissions. ONWARD benefits from partnerships with leading rehabilitation centers and a growing awareness of neuromodulation therapies. The market opportunity is substantial, with over 300,000 people living with SCI in the US alone. As ONWARD transitions from a development-stage to a commercial-stage company, successful regulatory approvals and market access will be key catalysts. The stock offers a high-risk, high-reward profile for investors focused on disruptive neurotechnology.

Upcoming Catalysts (preview)

• 2026US FDA Approval Decision for ARC EX System60% success
• H2 2026Pivotal Trial Results in Upper Limb Function70% success
• 2026European Distribution Partnership Announcement50% success